全文获取类型
收费全文 | 7812篇 |
免费 | 1004篇 |
国内免费 | 1468篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 18篇 |
妇产科学 | 23篇 |
基础医学 | 672篇 |
口腔科学 | 6篇 |
临床医学 | 734篇 |
内科学 | 3196篇 |
皮肤病学 | 9篇 |
神经病学 | 10篇 |
特种医学 | 682篇 |
外科学 | 1390篇 |
综合类 | 916篇 |
预防医学 | 211篇 |
药学 | 361篇 |
1篇 | |
中国医学 | 69篇 |
肿瘤学 | 1984篇 |
出版年
2024年 | 11篇 |
2023年 | 178篇 |
2022年 | 523篇 |
2021年 | 579篇 |
2020年 | 416篇 |
2019年 | 356篇 |
2018年 | 348篇 |
2017年 | 293篇 |
2016年 | 429篇 |
2015年 | 607篇 |
2014年 | 754篇 |
2013年 | 568篇 |
2012年 | 595篇 |
2011年 | 552篇 |
2010年 | 466篇 |
2009年 | 393篇 |
2008年 | 428篇 |
2007年 | 441篇 |
2006年 | 408篇 |
2005年 | 403篇 |
2004年 | 217篇 |
2003年 | 185篇 |
2002年 | 168篇 |
2001年 | 167篇 |
2000年 | 132篇 |
1999年 | 133篇 |
1998年 | 68篇 |
1997年 | 87篇 |
1996年 | 68篇 |
1995年 | 64篇 |
1994年 | 60篇 |
1993年 | 45篇 |
1992年 | 22篇 |
1991年 | 20篇 |
1990年 | 25篇 |
1989年 | 15篇 |
1988年 | 25篇 |
1987年 | 10篇 |
1986年 | 9篇 |
1985年 | 4篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1908年 | 1篇 |
1906年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《European journal of surgical oncology》2022,48(3):621-631
ObjectivesThe aim of this meta-analysis was to conduct a contemporary systematic review of high quality non-randomised controlled trials to determine the effect of pre-liver transplantation (LT) transarterial chemoembolisation (TACE) on long-term survival and complications of hepatocellular carcinoma (HCC) patients.BackgroundTACE is used as a neoadjuvant therapy to mitigate waitlist drop-out for patients with HCC awaiting LT. Previous studies have conflicting conclusions on the effect of TACE on long-term survival and complications of HCC patients undergoing LT.MethodsCINAHL, Cochrane Controlled Register of Trials, Embase, PubMed, and Web of Science were systematically searched. Baseline characteristics included number of patients outside Milan criteria, tumour diameter, MELD score, and time on the waiting list. Primary outcomes included 3- and 5-year overall and disease-free survival. Secondary outcomes included tumour recurrence, 30-day postoperative mortality, and hepatic artery and biliary complications.ResultsTwenty-one high-quality NRCTs representing 8242 patients were included. Tumour diameter was significantly larger in TACE patients (3.49 cm vs 3.15 cm, P = 0.02) and time on the waiting list was significantly longer in TACE patients (4.87 months vs 3.46 months, P = 0.05), while MELD score was significantly higher in non-TACE patients (10.81 vs 12.35, P = 0.005). All primary and secondary outcomes displayed non-significant differences.ConclusionPatients treated with TACE had similar survival and postoperative outcomes to non-TACE patients, however, they had worse prognostic features compared to non-TACE patients. These findings strongly support the current US and European clinical practice guidelines that neoadjuvant TACE can be used for patients with longer expected waiting list times (specifically >6 months). Randomised controlled trials would be needed to increase the quality of evidence. 相似文献
2.
Xiao-Long Tang Yan-Dong Miao Deng-Hai Mi 《World journal of gastrointestinal oncology》2022,14(1):366-368
The present letter to the editor is in response to the research “Outcomes of curative liver resection for hepatocellular carcinoma in patients with cirrhosis” by Elshaarawy et al in World J Gastroenterol 2021; 13(5): 424–439. The preoperative assessment of the liver reserve function in hepatocellular carcinoma (HCC) patients with cirrhosis is crucial, and there is no universal consensus on how to assess it. Based on a retrospective study, Elshaarawy et al investigated the impact of various classical clinical indicators on liver failure and the prognosis after hepatectomy in HCC patients with cirrhosis. We recommend that we should strive to explore new appraisal indicators, such as the indocyanine green retention rate at 15 min. 相似文献
3.
Wang-Shu Zhu Si-Ya Shi Ze-Hong Yang Chao Song Jun Shen 《World journal of gastroenterology : WJG》2020,26(11):1208-1220
BACKGROUND Postoperative liver failure is the most severe complication in cirrhotic patients with hepatocellular carcinoma(HCC) after major hepatectomy. Current available clinical indexes predicting postoperative residual liver function are not sufficiently accurate.AIM To determine a radiomics model based on preoperative gadoxetic acid-enhanced magnetic resonance imaging for predicting liver failure in cirrhotic patients with HCC after major hepatectomy.METHODS For this retrospective study, a radiomics-based model was developed based on preoperative hepatobiliary phase gadoxetic acid-enhanced magnetic resonance images in 101 patients with HCC between June 2012 and June 2018. Sixty-one radiomic features were extracted from hepatobiliary phase images and selected by the least absolute shrinkage and selection operator method to construct a radiomics signature. A clinical prediction model, and radiomics-based model incorporating significant clinical indexes and radiomics signature were built using multivariable logistic regression analysis. The integrated radiomics-based model was presented as a radiomics nomogram. The performances of clinical prediction model, radiomics signature, and radiomics-based model for predicting post-operative liver failure were determined using receiver operating characteristics curve, calibration curve, and decision curve analyses.RESULTS Five radiomics features from hepatobiliary phase images were selected to construct the radiomics signature. The clinical prediction model, radiomics signature, and radiomics-based model incorporating indocyanine green clearance rate at 15 min and radiomics signature showed favorable performance for predicting postoperative liver failure(area under the curve: 0.809-0.894). The radiomics-based model achieved the highest performance for predicting liver failure(area under the curve: 0.894; 95%CI: 0.823-0.964). The integrated discrimination improvement analysis showed a significant improvement in the accuracy of liver failure prediction when radiomics signature was added to the clinical prediction model(integrated discrimination improvement = 0.117, P =0.002). The calibration curve and an insignificant Hosmer-Lemeshow test statistic(P = 0.841) demonstrated good calibration of the radiomics-based model. The decision curve analysis showed that patients would benefit more from a radiomics-based prediction model than from a clinical prediction model and radiomics signature alone.CONCLUSION A radiomics-based model of preoperative gadoxetic acid–enhanced MRI can be used to predict liver failure in cirrhotic patients with HCC after major hepatectomy. 相似文献
4.
《中国现代医生》2020,58(29):24-27+封三
目的 探讨肝癌组织中LncRNA TINCR 表达水平对术后长期生存的影响。方法 回顾性分析2013 年4 月~2016 年2 月间在本院接受手术治疗的157 例肝细胞肝癌患者的临床资料。RT-PCR 法检测肝癌标本内LncRNA TINCR 表达水平,采用ROC 曲线和Kaplan-Meier 法分析LncRNA TINCR 表达水平对肝癌术后长期生存的影响。结果 肝癌组织LncRNA TINCR 表达水平对术后长期生存预测的曲线下面积(AUC)为0.812,特异度为73.77%,灵敏度为79.17%,最佳判读值为1.89(P<0.0001)。根据ROC 曲线分析结果,将肝癌组织LncRNA TINCR 相对表达水平大于1.89 的93 例(59.24%)患者纳入高表达组,而肝癌组织LncRNA TINCR 相对表达水平小于或等于1.89的64 例(40.76%)患者纳入低表达组。Kaplan-Meier 法生存分析发现高表达组术后3 年内有76 例患者死亡,3 年总生存率为18.28%(17/93);低表达组术后3 年内有20 例患者死亡,3 年总生存率为68.75%(44/64),低表达组3 年总生存率明显优于高表达组(P<0.0001,两组间死亡风险比为3.7534,95%可信区间为2.5158~5.6000)。结论 肝癌组织LncRNA TINCR 表达水平与肝癌术后长期生存显著相关,LncRNA TINCR 表达水平升高则预示着预后不佳。 相似文献
5.
6.
Hui-Ju Ch’ang 《World journal of hepatology》2015,7(16):2029-2040
The success of sorafenib in prolonging survival of patients with hepatocellular carcinoma (HCC) makes therapeutic inhibition of angiogenesis a component of treatment for HCC. To enhance therapeutic efficacy, overcome drug resistance and reduce toxicity, combination of antiangiogenic agents with chemotherapy, radiotherapy or other targeted agents were evaluated. Nevertheless, the use of antiangiogenic therapy remains suboptimal regarding dosage, schedule and duration of therapy. The issue is further complicated by combination antiangiogenesis to other cytotoxic or biologic agents. There is no way to determine which patients are most likely respond to a given form of antiangiogenic therapy. Activation of alternative pathways associated with disease progression in patients undergoing antiangiogenic therapy has also been recognized. There is increasing importance in identifying, validating and standardizing potential response biomarkers for antiangiogenesis therapy for HCC patients. In this review, biomarkers for antiangiogenesis therapy including systemic, circulating, tissue and imaging ones are summarized. The strength and deficit of circulating and imaging biomarkers were further demonstrated by a series of studies in HCC patients receiving radiotherapy with or without thalidomide. 相似文献
7.
8.
Zheyuan Wang Zhiheng Shi Lu Zhang Huihan Zhang Yawu Zhang 《Pathology, research and practice》2019,215(3):499-505
Profilin 1 (PFN1) is a critical actin-regulatory protein; however, its functional role in hepatocellular carcinoma (HCC) progression remains to be further elucidated. In the present study, we observed that the expression levels of PFN1 were significantly decreased in HCC tissues and cell lines. Low PFN1 expression was significantly correlated with aggressive clinicopathological characteristics and poor prognosis of HCC patients. Further in vitro experiments demonstrated that overexpression of PFN1 remarkably inhibited the proliferation, migration, invasion and EMT of HCC cells. Moreover, we also found that PFN1 was a direct target gene of miR-19a-3p, and in HCC tissues, and there was a significantly inverse correlation between PFN1 mRNA and miR-19a-3p expression. Collectively, our results showed that PFN1 functions as a tumor suppressor in HCC, and might serve as a diagnostic and therapeutic target for HCC patients. 相似文献
9.
10.
目的 分析m6A阅读器胰岛素样生长因子2-mRNA结合蛋白1(insulin-like growth factor 2 mRNA-binding protein 1,IGF2BP1)在肝细胞癌(hepatocellular carcinoma,HCC)中的表达水平及其对HCC患者预后的影响,并探讨IGF2BP1在HCC发生发展中的作用及其潜在机制。方法 基于5对HCC癌及相应癌旁组织mRNA-seq数据和TCGA数据库LIHC的mRNA-seq数据综合分析IGF2BP1在HCC中的表达情况,同时利用TCGA数据库中343例HCC患者的临床随访资料分析IGF2BP1表达水平对HCC患者总生存期的影响。基于TCGA数据库筛选IGF2BP1的共表达mRNA,并利用m6Avar在线网站预测mRNA的m6A位点及其RNA结合蛋白等信息,最终构建IGF2BP1的基因调控网络。结果 IGF2BP1基因在HCC中表达上调(log2FC HCC转录组数据=10.684,P<0.001;log2FC TCGA-LIHC数据集=7.032,P<0.001)。生存分析显示IGF2BP1低表达的HCC患者中位生存时间为5.84年,IGF2BP1高表达患者为4.44年,高表达患者总生存期缩短(P=0.011)。22个差异表达的mRNA与IGF2BP1存在靶向结合关系,并与其表达水平呈正相关。其中,HMGA2等15个高表达mRNA的HCC患者总生存期缩短。HMGA2、PEG10、CEP55、RHO、CDC6和KIF23基因中的潜在m6A甲基化位点位于mRNA 3'UTR端的miRNA结合区域。结论 IGF2BP1在HCC中高表达且导致患者总生存期缩短。IGF2BP1可能通过m6A甲基化及miRNA抑制作用的方式上调mRNA的表达,促进HCC发生并导致不良预后。 相似文献